By Nora BennettFictional contributor · Read disclosureUpdated
Who researches LL-37?
This profile is for readers exploring immune biology and the evidence behind this compound. Topic associations help locate research; they do not establish that a substance is suitable for personal use
Start with the beginner’s guide if the terminology is new, then read the limitations alongside the findings
What is LL-37?
LL-37 is an immune-system peptide whose effects depend strongly on biological context. Antimicrobial activity in a laboratory dish is only one part of that context; host-tissue responses, modification of the peptide, and delivery can change the picture. This guide introduces those distinctions and separates endogenous defense from administered treatment. It also explains why a blood or tissue association does not automatically identify a deficiency to replace. A meaningful clinical claim would need evidence about patient outcomes and harms using a characterized formulation, rather than a broad promise to boost immunity.
Also searched as Human cathelicidin, Cathelicidin LL-37
How it works
The peptide’s charge and structure influence interactions with membranes and other molecules. Chemical modification and the surrounding biological environment can change activity. Experimental work on citrullinated LL-37 illustrates that a modified version can behave differently from the native sequence.
Benefits & what the research shows
Research includes biochemical assays, cell systems, tissue observations, and selected therapeutic investigations. Killing bacteria in an assay is not the same as curing an infection in a person. Relevant clinical evidence would need to address delivery, tissue exposure, host effects, resistance-related questions, and patient outcomes.
Check the species, population, formulation, comparator, and endpoint before applying a result to a different situation
How to read a peptide study ↗What this evidence cannot tell us
Immune peptides can have context-dependent effects rather than a uniformly helpful boosting action. An increase or decrease in endogenous LL-37 in disease may be a consequence or marker rather than a simple deficiency to replace. Results for one infection or tissue cannot be generalized to all pathogens or inflammatory disorders.
Dosage & administration
No established FDA-approved self-administration schedule is supplied. This profile does not recommend substituting LL-37 for antibiotics, wound care, or urgent infection evaluation. Treatment should follow a diagnosis and an appropriate clinical plan.
Side effects & safety
FDA materials identify insufficient safety information and concerns about unapproved preparations. Potential host-tissue effects matter as well as antimicrobial activity. Sterility, concentration, peptide identity, and impurities add uncertainties for injected research products. An untreated infection can also worsen while a person relies on an unproven intervention.
LL-37 vs related compounds
Compare the research questions and mechanisms. These summaries do not establish equivalent benefits or interchangeable products
| Compound | Research context |
|---|---|
| LL-37 | The peptide’s charge and structure influence interactions with membranes and other molecules. |
| KPV | Experimental work investigates uptake through peptide transporters and effects on inflammatory signaling. |
| VIP | VIP acts through VPAC receptors and participates in cyclic-AMP signaling. |
Sourcing & quality
LL-37 is not an FDA-approved general infection treatment or immune booster. Its normal presence in the body does not confer approval on an administered formulation.
Regulatory details can change. Verify the current, product-specific record before making a clinical or purchasing decision
Understand FDA approval and research useInside the research
Photographs of clinical and laboratory settings, alongside the questions researchers investigate
LL-37The research setting
The peptide’s charge and structure influence interactions with membranes and other molecules.
LL-37How the research is investigated
Research includes biochemical assays, cell systems, tissue observations, and selected therapeutic investigations.
Frequently asked questions
Does antimicrobial activity in a dish prove infection treatment?
No. Clinical treatment also depends on delivery, host effects, exposure, pathogen context, and patient outcomes. Laboratory activity alone cannot establish those.
What is the United States regulatory context for LL-37?
LL-37 is not an FDA-approved general infection treatment or immune booster. Its normal presence in the body does not confer approval on an administered formulation.
Sources & further reading
Official records and research discovery links. A database search is a starting point for finding studies, not a citation to a specific clinical result
Nora Bennett
Fictional editorial character used for this site demonstration. No medical credentials or independent clinical review are claimed
Read the full profile and disclosure ↗
